Received Oct 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | — |
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | UNK | — | — |
vaccine interchange; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of interchange of vaccine products in a 16-year-old female patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included Meningococcal vaccine B rfHbpA/fHbpB (Trumenba) for prophylaxis. In APR-2025, the patient received the 1st dose of Bexsero. On 06-OCT-2025, the patient received Trumenba. On 06-OCT-2025, an unknown time after receiving Bexsero and Trumenba, the patient experienced interchange of vaccine products (Verbatim: vaccine interchange). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: The pharmacist reported that a patient came in to receive a Meningococcal B vaccine yesterday and they only have Trumenba. Her first dose was Bexsero in April 2025 and Trumenba was given one day before reporting. The batch number was not provided upon follow up with the reporter.